Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...

SAFE Structure Designs, an American defense engineering and manufacturing company specializing in mission-critical military support equipment, announced the successful design and delivery of a custom ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

The narrative followed the structure evaluators expect to see. On paper, the proposal was strong. Yet as I read through the response, something felt strangely absent. The organization had demonstrated ...